Policy / Regulatory

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
VBP (voluem-based procurement)

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

The National Joint Procurement Office issued the Announcement on the Information Change Work for Selected Products in National Organization of Drug Volume‑Based Procurement, permitting – when selected enterprises and their…

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Genomics / NGSNovartis

Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act

SAMR

Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry

NDRC

China Unveils 16-Measure Policy to Support Overseas Investment in Domestic Tech Firms

FinanceIPO

China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises

Show More